Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia

25 Oct 2016

Abstract excerpt

Abstract Purpose: Human exportin-1 (XPO1) is the key nuclear-cytoplasmic transport protein that exports different cargo proteins out of the nucleus. Inducing nuclear accumulation of these proteins by inhibiting XPO1 causes cancer cell death. First clinical validation of pharmacological inhibition of XPO1 was obtained with the Selective Inhibitor of Nuclear Export (SINE) compound selinexor (KPT-330) demonstrating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Nuclear Structure and Function

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27780859
DOI: 10.1158/1078-0432.ccr-16-1580

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic LeukemiaPMID 27780859Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agentsSemantic proximity Read ↗

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agentsSemantic proximity Read ↗

<scp>KPT</scp>‐330 inhibitor of <scp>CRM</scp>1 (<scp>XPO</scp>1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of <scp>T</scp>‐cell acute lymphoblastic leukaemia and acute myeloid leukaemiaSemantic proximity Read ↗

Targeting XPO1-Dependent Nuclear Export in Cancer.Semantic proximity Read ↗

Targeting nuclear import and export in hematological malignanciesSemantic proximity Read ↗

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemiaSemantic proximity Read ↗

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsSemantic proximity Read ↗

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Semantic proximity Read ↗

Inhibiting cancer cell hallmark features through nuclear export inhibitionSemantic proximity Read ↗

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian CancerSemantic proximity Read ↗

Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.